A bold new trial is offering hope to those facing a deadly health threat, and a Leicestershire farmer is leading the way. But here's where it gets controversial: could a diabetes drug be the key to treating aneurysms?
Philip Gosling, an 80-year-old farmer, is among the pioneers in the UK to join this groundbreaking study. The trial, led by the University of Leicester, aims to discover if metformin, a common diabetes medication, can halt or prevent the growth of abdominal aortic aneurysms (AAA).
Mr. Gosling's journey began with an abdominal scan that revealed his AAA, a potentially life-threatening condition. However, his aneurysm was not yet at a critical stage, leaving him with few options other than waiting for it to worsen.
"I asked what I could do to stop it growing, and that's when they told me about the trial," Mr. Gosling shared.
The trial offers not only a potential treatment but also close monitoring of his condition, which Mr. Gosling hopes will benefit many others in the future.
An AAA often remains asymptomatic until it ruptures, but Mr. Gosling has made changes to his lifestyle, such as avoiding heavy lifting on the farm.
In the first phase of the trial, Mr. Gosling was gradually introduced to metformin to ensure his body tolerated the drug. He then progressed to the next stage, where he is now taking either metformin or a placebo, with regular check-ups to monitor his AAA's growth.
This trial is the largest of its kind for AAA and aims to find the first drug-based treatment for a condition that claims around 4,000 lives in the UK each year.
The UK branch, funded by a substantial grant from the British Heart Foundation, aims to recruit 1,000 patients over two years.
According to the university, the risk of rupture becomes significantly higher when the AAA reaches 5.5cm, and slowing its growth could prevent the need for major surgery.
Prof. Matt Brown, from the Department of Cardiovascular Sciences, believes metformin could be the long-sought treatment for AAA. "Research suggests it works by blocking inflammation in the aorta, a key factor in AAA enlargement," he explained.
The university's data shows that metformin has already led to a reduced rate of ruptures and surgical repairs among patients with type 2 diabetes. Now, the trial aims to determine if this is true for non-diabetic patients as well.
And this is the part most people miss: this trial could revolutionize the way we treat aneurysms, offering a new lease of life to those at risk.
What are your thoughts on this potential breakthrough? Do you think this trial could change the game for aneurysm treatment? We'd love to hear your opinions in the comments!
